Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Armodafinil
Drug ID BADD_D00167
Description Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Indications and Usage Investigated for use/treatment in sleep disorders, obstructive sleep apnea, schizophrenia and schizoaffective disorders, depression, and bipolar disorders.
Marketing Status Prescription; Discontinued
ATC Code N06BA13
DrugBank ID DB06413
KEGG ID D03215
MeSH ID D000077408
PubChem ID 9690109
TTD Drug ID D0J5RN
NDC Product Code 65862-807; 71335-0681; 0093-3090; 0093-3092; 0093-3094; 63459-220; 0781-8029; 63285-827; 63459-215; 63629-7403; 65862-806; 65129-1185; 65015-784; 0781-8053; 63285-033; 71335-1193; 68788-7826; 65862-805; 55700-510; 63459-205; 11722-072; 71335-1308; 63285-032; 63459-225; 68180-572; 72189-041; 72189-133; 68788-7593; 0781-8037; 63285-030; 65862-998; 0378-3431; 68788-7880; 65862-795; 68180-569; 0378-3433; 71335-1842; 0378-3432; 72189-261; 59651-047; 71335-1857; 63629-7390; 0781-8045; 68180-573; 0093-3093; 48087-0066; 72789-060; 68180-571; 72789-126; 11722-055; 68788-7176; 71335-0710; 68788-7222
Synonyms Modafinil | 2-((Diphenylmethyl)sulfinyl)acetamide | Vigil | Sparlon | Nuvigil | Alertec | Benzhydrylsulfinylacetamide | Armodafinil | 2-((R)-(Diphenylmethyl)sulfinyl)acetamide | R-Modafinil | R Modafinil | Provigil | Modiodal | CRL 40476 | CRL-40476
Chemical Information
Molecular Formula C15H15NO2S
CAS Registry Number 112111-43-0
SMILES C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tachycardia02.03.02.0070.006844%Not Available
Tension19.06.02.005--Not Available
Thirst14.03.02.007; 08.01.09.0210.002281%Not Available
Throat tightness22.02.05.015; 19.01.02.0050.002281%Not Available
Tic19.11.04.001; 17.02.05.0240.002281%Not Available
Tongue blistering07.14.02.0140.002281%Not Available
Tremor17.01.06.0020.005703%
Unresponsive to stimuli17.02.05.0310.002281%Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.0090.004562%
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.0010.006844%
Vision blurred17.17.01.010; 06.02.06.0070.003422%
Visual impairment06.02.06.0080.005703%Not Available
Vomiting07.01.07.003--
Weight increased13.15.01.0060.003422%
Seasonal allergy06.04.01.013; 22.04.04.008; 10.01.04.001--Not Available
Brain oedema17.07.02.003; 12.01.10.0100.000893%
Lip blister23.03.01.016; 07.05.01.0070.002281%Not Available
Balance disorder17.02.02.0070.002281%Not Available
Contusion24.07.06.001; 23.03.11.002; 15.03.01.008; 12.01.06.0010.003422%
Deep vein thrombosis24.01.02.003--Not Available
Malignant neoplasm progression16.16.01.0050.000893%Not Available
Drug tolerance08.06.01.0030.002281%Not Available
Gaze palsy17.02.05.044; 06.05.02.0140.002281%Not Available
Lung neoplasm malignant16.19.02.001; 22.08.01.0010.000595%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
Cardiac disorder02.01.01.0030.000595%Not Available
Malnutrition14.03.02.004--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages